Cancer-specific dose and fractionation schedules in stereotactic body radiotherapy for oligometastatic disease: An interim analysis of the EORTC-ESTRO E < sup > 2 < /sup > -RADIatE OligoCare study

CONCLUSION: This real-world analysis suggests that SBRT doses are adjusted to the primary cancers and oligometastasis location. Future analysis will address safety and efficacy of this site- and disease-adapted SBRT fractionation approach (NCT03818503).PMID:38508239 | DOI:10.1016/j.radonc.2024.110235

Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology - March 20, 2024 Category: Radiology Authors: Sebastian M Christ Filippo Alongi Umberto Ricardi Marta Scorsetti Lorenzo Livi Panagiotis Balermpas Yolande Lievens P ètra Braam Barbara Alicja Jereczek-Fossa Karin Stellamans Ivica Ratosa Joachim Widder Heike Peulen Piet Dirix Samuel Bral Sara Ramella H Source Type: research